RMD

ResMed Inc. 10-Q Summary: Quarter Ended March 31, 2000

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep disordered breathing. The report covers the three and nine-month periods ended March 31, 2000. Principal manufacturing operations are located in Australia, with major distribution sites in the United States, United Kingdom, and Europe.

Key Financial Metrics

Liquidity: As of March 31, 2000, the company held $16.36 million in cash and cash equivalents and $7.93 million in marketable securities. Total current assets were $71.53 million against current liabilities of $23.99 million.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 32% year-over-year for both the quarter ($7.2M increase) and the nine-month period ($20.6M increase). Growth was driven by increased unit sales of flow generators and accessories in North America, Latin America, Europe, and the Asia Pacific.
• Profitability: Gross profit margins improved to 66% for the quarter and 68% for the nine-month period, up from 65% and 67% respectively in the prior year. This was attributed to a favorable shift in geographical sales mix and improved manufacturing capacity utilization.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 44% for the quarter and 35% for the nine-month period, primarily due to hiring additional sales personnel (increasing from 197 to 264) and new office costs in Europe. R&D expenses increased 39% for the quarter to support new product development.
• Foreign Currency: Other income improved significantly due to foreign currency gains associated with the weakening Australian dollar. However, foreign currency translation adjustments resulted in a net loss of $5.7 million for the quarter, compared to a gain of $0.15 million in the prior year.

Outlook, Risks, and Contingencies

• Management Commentary: Management attributes growth to strong demand and strategic inventory increases in the US and Europe to support the launch of the ResMed S6 CPAP range and Ultra Mirage masks. Capital expenditures decreased to $8.2 million for the nine-month period compared to $17.9 million previously, as the new manufacturing facility was completed in March 1999.
• Acquisitions: On January 31, 2000, the company acquired its Swedish distributor, Einar Egnell AB, for $576,000 in cash.
• Legal Proceedings: Significant ongoing litigation includes patent infringement disputes with Respironics (where summary judgment motions have been granted against ResMed, with an appeal planned) and a new lawsuit filed March 31, 2000, against MPV Truma and Tiara Medical Systems regarding trademark and design patent infringement. Additionally, ResMed is defending a claim in Australia alleging unfair trade practices.
• Market Risk: The company faces substantial exposure to fluctuations in the Australian dollar and Euro. It utilizes foreign currency option contracts (notional amount of $144.1 million as of March 31, 2000) to hedge these risks.
• Accounting Changes: The company notes upcoming adoption of SFAS No. 133 (Derivatives) and SAB 101 (Revenue Recognition), though it does not currently expect a material impact from SAB 101.

Investor Verification Checklist

• Verify the status and potential financial impact of the pending patent litigation with Respironics and the new lawsuit against MPV Truma/Tiara Medical Systems.
• Monitor the effectiveness of foreign currency hedging strategies given the significant exposure to the Australian dollar and recent translation losses.
• Assess the sustainability of SG&A expense growth relative to revenue as the company continues to expand its sales force and international footprint.
• Review the integration and performance of the newly acquired Swedish distributor, Einar Egnell AB.
• Confirm the impact of upcoming accounting standard changes (SFAS 133) on future financial reporting.